Spinal Muscular Atrophy Type 1

Key facts

  • Spinal muscular atrophy (SMA) is an autosomal recessive disorder characterised by progressive muscle weakness owing to the degeneration and loss of the anterior horn cells (the lower motor neurons) in the spinal cord and the brain stem nuclei.
  • SMA occurs in about 1 in 25,000 individuals in the UK, with a carrier frequency of 1 in 50-80.
  • SMA is caused by an alteration in the SMN1 gene on chromosome 5.
  • DNA testing is now the preferred method of diagnosis.
  • Once the diagnosis has been made, an individual needs careful and ongoing assessments to establish their personal needs. This often includes assistance with feeding and ventilation, as well as mobility and physiotherapy support.

Clinical features

  • SMA is characterised by progressive muscle weakness. Implications of this include an inability to sit or walk, and respiratory difficulties. Intelligence and brain development remain unaffected.
  • The condition is extremely variable and the onset of weakness ranges from before birth to early adulthood.
  • Before the genetic basis of SMA was understood, the condition was classified into clinical subtypes (see below) based on the age of onset of symptoms.

Diagnosis

The five main subtypes of SMA are described in this section. This classification is still useful for both management and prognosis, though it is now apparent that there is no clear delineation between them; the different subtypes form a continuum of disease symptoms, all of which are caused by genetic alteration (mutations) in the SMN1 gene.

    • SMA 0: Prenatal onset of symptoms, usually fatal in the first six months of life.
    • SMA I (Werdnig-Hoffman disease): Onset before six months of age. Infants may present with a ‘frog leg’ posture due to muscle weakness and hypotonia. Facial weakness is minimal or absent. Life expectancy is normally less than 2 years.
    • SMA II: Onset between six and 18 months. >70% affected individuals have a life expectancy over 25 years.
    • SMA III (Kugelberg-Welander syndrome): Onset in childhood after 12 months. Normal life expectancy.
    • SMA IV: Adult onset. Normal life expectancy.
  • Other forms of SMA have been described and may not be associated with alterations in SMN1. For example, about 50% of babies with SMA 0 are due to alterations in other genes.
  • Other investigations including creatine kinase levels may be important if the diagnosis of SMA cannot be established by SMN1 testing.

Genetic basis

  • Inheritance is autosomal recessive, but 2% of affected individuals have one de novo genetic alteration, meaning that only one parent is a carrier. Recurrence risks in this situation are considerably lower.
  • SMA is caused by genetic alterations in the motor neuron 1 gene (SMN1) on chromosome 5. About 95% of individuals with SMA share a common genetic alteration.
  • The genetic basis of SMA is complex and alterations in a second gene, SMN2, which is adjacent to SMN1, are known to modify the phenotype. Referral to the local clinical genetics service is advised.

Clinical management

  • SMA I is a life-limiting illness and appropriate management, including palliative care, should be given with full discussion and support from the parents. Prolonged survival may be achieved with ventilation, feeding and physiotherapy support.
  • Individuals with other forms of SMA may require mobility assistance, physiotherapy, assistance with feeding and nocturnal ventilation.
  • SMA is a condition where needs may change with time. Receiving optimum care from a multidisciplinary team, with input of a number of healthcare professionals, may improve the quality of life of an individual with SMA.
  • An individual with SMA and his or her family should be actively engaged with the process of individualising care. 'A Family Guide to the Consensus Statement for Standard of Care in Spinal Muscular Atrophy', published in 2007, is a useful booklet designed to help with this process

Genetic testing

Indications for genetic testing and genetic counselling include:

  • confirmation of the diagnosis in an individual suspected of having SMA;
  • siblings and relatives of affected children with symptoms suggestive of the condition;
  • two individuals who are carriers contemplating a pregnancy who may consider prenatal or pre-implantation genetic diagnosis. Prenatal diagnosis is usually possible by chorionic villus sampling (CVS) or amniocentesis. If a couple are considering prenatal diagnosis, referral should be made to the local clinical genetics service prior to a pregnancy. This ensures that appropriate advice and investigations are undertaken and confirms whether or not prenatal diagnosis is possible. All couples considering pre-implantation genetic diagnosis must be referred to their local clinical genetics service.
  • to provide information about the genetic status of other relatives of someone with SMA through carrier testing; and
  • presence of features suggestive of SMA on routine antenatal ultrasound scans, even when that pregnancy is not known to be at increased risk.

This information is intended for educational use and was current in March 2015. For clinical management, it is recommended that local guidelines and protocols are used.

Originally developed by the NHS National Genetics and Genomics Education Centre, and updated in collaboration with Birmingham Women’s NHS Foundation Trust’s Clinical Genetics department.